Comprehensive Psychiatry
Volume 44, Issue 5 , Pages 360-369 , September 2003

Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline

  • Kathleen T Brady

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Kathleen T. Brady, Ph.D., M.D., Medical University of South Carolina, 67 President St, PO Box 250861, Charleston, SC 29425, USA
    • Medical University of South Carolina, Charleston, SC, USA
    • ,
  • Cathryn M Clary

      Affiliations

    • Pfizer, Inc, USA

References 

  1. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1995;52:1048–1060
  2. Breslau N, Davis GC, Andreski P, Peterson E. Traumatic events and posttraumatic stress disorder in an urban population of young adults. Arch Gen Psychiatry. 1991;48:216–222
  3. Resnick HS, Kilpatrick DG, Dansky BS, Saunders BE, Best CL. Prevalence of civilian trauma and posttraumatic stress disorder in a representative national sample of women. J Consult Clin Psychol. 1993;61:984–991
  4. Bureau of Justice statistics. http://www.ojp.usdoj.gov/bjs/glance/tables/viortrdtab.htm
  5. Stein MB, Walker JR, Hazen AL, Forde DR. Full and partial posttraumatic stress disorder (findings from a community survey). Am J Psychiatry. 1997;154:1114–1119
  6. Breslau N, Davis GC, Peterson EL, Schultz LR. A second look at comorbidity in victims of trauma (the posttraumatic stress disorder-major depression connection). Biol Psychiatry. 2000;48:902–909
  7. Chilcoat HD, Breslau N. Posttraumatic stress disorder and drug disorders (Testing causal pathways). Arch Gen Psychiatry. 1998;55:913–917
  8. Lecrubier Y, Ustun TB. Panic and depression (a worldwide primary care perspective). Int Clin Psychopharmacol. 1998;13(4 Suppl):S7–S11
  9. Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG, et al.  Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry. 1997;154:1734–1740
  10. Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population (results from the US National Comorbidity Survey). Br J Psychiatry. 1996;(Suppl):17–30
  11. Andrews G, Slade T, Issakidis C. Deconstructing current comorbidity (data from the Australian National Survey of Mental Health and Well-Being). Br J Psychiatry. 2002;181:306–314
  12. Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:355–364
  13. Kaplan MJ, Klinetob NA. Childhood emotional trauma and chronic posttraumatic stress disorder in adult outpatients with treatment-resistant depression. J Nerv Ment Dis. 2000;188:596–601
  14. Frank E, Shear MK, Rucci P, Cyranowski JM, Endicott J, Fagiolini A, et al.  Influence of panic-agoraphobic spectrum symptoms on treatment response in patients with recurrent major depression. Am J Psychiatry. 2000;157:1101–1107
  15. Lecrubier Y. The impact of comorbidity on the treatment of panic disorder. J Clin Psychiatry. 1998;59(8 Suppl):11–14
  16. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, et al.  Double-blind, placebo-controlled study of the efficacy and safety of sertraline treatment of posttraumatic stress disorder. JAMA. 2000;283:1837–1844
  17. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58:485–492
  18. Spitzer RL, Williams JBW, Gibbon M. Instruction Manual for the Structured Clinical Interview for DSM-III-R. New York, NY: Biometrics Research Division, State Psychiatry Research Institute; 1987;
  19. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington, DC: National Institute of Mental Health-US Dept of Health, Education, and Welfare publication (ADM); 1976; 76–338
  20. Horowitz M, Wilner N, Alvarez W. Impact of Event Scale (a measure of subjective stress). Psychosom Med. 1979;41:209–218
  21. Zilberg N, Weiss D, Horowitz M. Impact of Event Scale (a cross-validation study). J Consult Clin Psychol. 1982;50:407–414
  22. Davidson JR, Book SW, Colket JT, et al.  Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med. 1997;27:153–160
  23. Zlotnick C, Davidson J, Shea MT, Pearlstein T. Validation of the Davidson Trauma Scale in a sample of survivors of childhood sexual abuse. J Nerv Ment Dis. 1996;184:255–257
  24. Hamilton MA. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62
  25. Endicott J, Nee J, Harrison W. Quality of Life Enjoyment and Satisfaction Questionnaire (a new measure). Psychopharmacol Bull. 1993;29:321–326
  26. Lydiard RB, Stahl SM, Hertzman M, Harrison WM. A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression. J Clin Psychiatry. 1997;58:484–491
  27. Rapaport MH, Pollack M, Wolkow R, Mardekian J, Clary C. Is placebo response the same as drug response in panic disorder?. Am J Psychiatry. 2000;157:1014–1016
  28. Koran LM, Hackett E, Rubin A, Wolkow R, Robinson D. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry. 2002;159:88–95
  29. Lepola U, Arato M, Austin C. Sertraline vs. imipramine treatment of comorbid panic disorder and major depression. J Clin Psychiatry. In press.
  30. Sheikh JI, Londborg P, Clary CM, Fayyad R. The efficacy of sertraline in panic disorder (combined results from two fixed-dose studies). Int Clin Psychopharmacol. 2000;15:335–342
  31. Hoehn-Saric R, Ninan P, Black DW, Stahl S, Greist JH, Lydiard B, et al.  Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch Gen Psychiatry. 2000;57:76–82
  32. Riskind JH, Beck AT, Brown G, Steer RA. Taking the measure of anxiety and depression. Validity of the reconstructed Hamilton scales. J Nerv Ment Dis. 1987;175:474–479
  33. Montgomery SA. The failure of placebo-controlled studies. ECNP Consensus Meeting, European College of Neuropsychopharmacology. Eur Neuropsychopharmacol. 1999;9:271–276

☆ Supported by Pfizer, Inc.

PII: S0010-440X(03)00111-1

doi: 10.1016/S0010-440X(03)00111-1

Comprehensive Psychiatry
Volume 44, Issue 5 , Pages 360-369 , September 2003

Article Tools

* Image Usage & Resolution